Inhibikase Therapeutics (IKT) News Today → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free IKT Stock Alerts $1.69 +0.03 (+1.81%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 5 at 8:05 AM | globenewswire.comInhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development ProgramsMay 21, 2024 | finance.yahoo.comInhibikase Therapeutics First Quarter 2024 Earnings: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)May 20, 2024 | globenewswire.comInhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionMay 19, 2024 | msn.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Call TranscriptMay 18, 2024 | investing.comEarnings call: Inhibikase Therapeutics reports on drug trials progressMay 16, 2024 | msn.comIKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024May 15, 2024 | globenewswire.comInhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityMay 15, 2024 | globenewswire.comInhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementMay 9, 2024 | globenewswire.comInhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionApril 22, 2024 | msn.comLexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare moversApril 20, 2024 | investing.comInhibikase Therapeutics progresses in Parkinson's disease trialsApril 18, 2024 | globenewswire.comInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsApril 3, 2024 | markets.businessinsider.comInhibikase Announces Pre-IND Meeting For IkT-001Pro - Quick FactsApril 3, 2024 | globenewswire.comInhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionApril 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory ProgressApril 2, 2024 | finance.yahoo.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comInhibikase Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 29, 2024 | finance.yahoo.comQ4 2023 Inhibikase Therapeutics Inc Earnings CallMarch 27, 2024 | globenewswire.comInhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityMarch 7, 2024 | finance.yahoo.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 6, 2024 | markets.businessinsider.comBuy Rating Backed by Promising Developments and Regulatory Confidence in Inhibikase’s PipelineMarch 5, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To KnowFebruary 28, 2024 | globenewswire.comInhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001ProFebruary 21, 2024 | markets.businessinsider.comInhibikase Therapeutics: Buy Rating Affirmed Amid Promising Drug Candidates and Strong Financial StandingFebruary 15, 2024 | finance.yahoo.comHere's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock NowFebruary 10, 2024 | investing.comInhibikase Therapeutics Inc (IKT)February 8, 2024 | msn.comInhibikase Discusses FDA Pathway for New Cancer DrugFebruary 7, 2024 | msn.comTenax Therapeutics, Equillium among healthcare moversFebruary 7, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal CancersFebruary 6, 2024 | msn.comNew Strong Buy Stocks for February 6thJanuary 29, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with RisvodetinibJanuary 22, 2024 | finance.yahoo.comInhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?January 17, 2024 | msn.comInhibikase Therapeutics appoints Lees-Rolfe as CFOJanuary 16, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph FrattaroliJanuary 5, 2024 | msn.comWhy Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving PremarketDecember 19, 2023 | finance.yahoo.comInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsDecember 15, 2023 | morningstar.comInhibikase Therapeutics Inc Ordinary SharesDecember 4, 2023 | markets.businessinsider.comInhibikase Therapeutics Gets FDA's Pre-NDA Meeting For IkT-001ProNovember 14, 2023 | seekingalpha.comInhibikase Therapeutics GAAP EPS of -$0.86November 13, 2023 | benzinga.comEarnings Preview For Inhibikase TherapeuticsNovember 7, 2023 | finance.yahoo.comInhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023November 7, 2023 | finance.yahoo.comCorrecting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023October 16, 2023 | finance.yahoo.comInhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing EnrollmentOctober 4, 2023 | markets.businessinsider.comInhibikase Therapeutics Announces Orphan Drug Designation For RisvodetinibOctober 4, 2023 | markets.businessinsider.comPromising Developments and Financial Outlook for Inhibikase Therapeutics Prompt Buy RatingOctober 4, 2023 | finance.yahoo.comInhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System AtrophySeptember 20, 2023 | finance.yahoo.comInhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading ActivityAugust 24, 2023 | finance.yahoo.comInhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Millionaire-Making “Wealth Pattern” Just Repeated on April 22 (Ad)If you think you missed out on the Bitcoin band wagon… You need to watch this immediately. This Crypto bull market is not even halfway over IKT Media Mentions By Week IKT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IKT News Sentiment▼0.000.73▲Average Medical News Sentiment IKT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IKT Articles This Week▼11▲IKT Articles Average Week Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALGS News OKYO News ACHL News CYTH News QNCX News NKGN News SRZN News INKT News PLUR News BCLI News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:IKT) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored